Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

Touchdown Novum Labs for Hydromars!

A new company has arrived in Flemingsberg, and they´re moving at rocket speed on their journey toward space. Meet Hydromars, the startup company developing a system for water purification and nutrient recovery, with a grand goal of enabling sustainable human presence in space.

Flemingsberg Science Foundation Summer Party 2025 – What’s Happening in Flemingsberg?

There was a time when that question was rarely asked – but that time is long gone!On Tuesday, June 10, 130 people gathered to celebrate the start of summer together. Business leaders, municipal and regional representatives, academia, and students came together under the theme “What’s Happening in Flemingsberg?” – an evening dedicated to sharing the latest developments: new establishments, initiatives, innovations, and future plans in Flemingsberg.

ATMP Sweden – now also in Flemingsberg!

The ATMP Sweden association carries out dedicated work focused on national coordination and communication to accelerate the development, accessibility, and implementation of advanced therapies (ATMP). And now they also have an office space at Novum Labs! From here, Henrik Simonsson, Communications and Operative Lead, can work on the association’s plans to take its operations to even more meaningful heights.